LVW Advisors LLC Lowers Stock Position in The Cooper Companies, Inc. (NASDAQ:COO)

LVW Advisors LLC reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 3.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,216 shares of the medical device company’s stock after selling 375 shares during the quarter. LVW Advisors LLC’s holdings in Cooper Companies were worth $939,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of COO. Ashton Thomas Securities LLC purchased a new position in shares of Cooper Companies during the third quarter worth approximately $25,000. Covestor Ltd raised its stake in shares of Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after acquiring an additional 200 shares in the last quarter. Brown Brothers Harriman & Co. raised its stake in shares of Cooper Companies by 191.0% during the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares in the last quarter. West Financial Advisors LLC purchased a new position in shares of Cooper Companies during the fourth quarter worth approximately $49,000. Finally, Friedenthal Financial purchased a new position in shares of Cooper Companies during the third quarter worth approximately $50,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Morgan Stanley decreased their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Citigroup decreased their target price on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Stock Performance

NASDAQ:COO opened at $93.27 on Monday. The stock has a market cap of $18.61 billion, a P/E ratio of 47.83, a price-to-earnings-growth ratio of 2.29 and a beta of 0.99. The firm’s fifty day simple moving average is $96.54 and its 200 day simple moving average is $99.08. The Cooper Companies, Inc. has a twelve month low of $84.76 and a twelve month high of $112.38. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the previous year, the business posted $0.87 EPS. The company’s quarterly revenue was up 9.8% on a year-over-year basis. As a group, research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.